EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of 3 Tests

Michael Szarek iD, Esther Reijnders iD, J Wouter Jukema iD, Deepak L Bhatt iD, Vera A Bittner iD, Rafael Diaz iD, Sergio Fazio iD, Genevieve Garon, Shaun G Goodman iD, Robert A Harrington iD, L Renee Ruhaak iD, Markus Schwertfeger und 6 weitere

Circulation · 16.01.2024 · 149 (3) · 192-203

DOI: 10.1161/circulationaha.123.066398 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation, erschienen am 16.01.2024. Verfasst von Michael Szarek und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, University of Colorado School of Medicine, Aurora (M. Szarek, G.G.S.). Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Anticholesteremic Agents, Hydroxymethylglutaryl-CoA Reductase Inhibitors. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Lipoprotein(a) is a risk factor for cardiovascular events and modifies the benefit of PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors. Lipoprotein(a) concentration can be measured with immunoassays reporting mass or molar concentration or a reference measurement system using mass spectrometry. Whether the relationships between lipoprotein(a) concentrations and cardiovascular events in a high-risk cohort differ across lipoprotein(a) methods is unknown. We compared the prognostic and predictive value of these types of lipoprotein(a) tests for major adverse cardiovascular events (MACE). METHODS: The ODYSSEY OUTCOMES trial (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) compared the PCSK9 inhibitor alirocumab with placebo in patients with recent acute coronary syndrome. We compared risk of a MACE in the placebo group and MACE risk reduction with alirocumab according to baseline lipoprotein(a) concentration measured by Siemens N-latex nephelometric immunoassay (IA-mass; mg/dL), Roche Tina-Quant turbidimetric immunoassay (IA-molar; nmol/L), and a noncommercial mass spectrometry–based test (MS; nmol/L). Lipoprotein(a) values were transformed into percentiles for comparative modeling. Natural cubic splines estimated continuous relationships between baseline lipoprotein(a) and outcomes in each treatment group. Event rates were also determined across baseline lipoprotein(a) quartiles defined by each assay. RESULTS: Among 11 970 trial participants with results from all 3 tests, baseline median (Q1, Q3) lipoprotein(a) concentrations were 21.8 (6.9, 60.0) mg/dL, 45.0 (13.2, 153.8) nmol/L, and 42.2 (14.3, 143.1) nmol/L for IA-mass, IA-molar, and MS, respectively. The strongest correlation was between IA-molar and MS (r=0.990), with nominally weaker correlations between IA-mass and MS (r=0.967) and IA-mass and IA-molar (r=0.972). Relationships of lipoprotein(a) with MACE risk in the placebo group were nearly identical with each test, with estimated cumulative incidences differing by ≤0.4% across lipoprotein(a) percentiles, and all were incrementally prognostic after accounting for low-density lipoprotein cholesterol levels (all spline P ≤0.0003). Predicted alirocumab treatment effects were also nearly identical for each of the 3 tests, with estimated treatment hazard ratios differing by ≤0.07 between tests across percentiles and nominally less relative risk reduction by alirocumab at lower percentiles for all 3 tests. Absolute risk reduction with alirocumab increased with increasing lipoprotein(a) measured by each test, with significant linear trends across quartiles. CONCLUSIONS: In patients with recent acute coronary syndrome, 3 lipoprotein(a) tests were similarly prognostic for MACE in the placebo group and predictive of MACE reductions with alirocumab at the cohort level. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01663402.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Coronary SyndromeAnticholesteremic AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsHumansProprotein Convertase 9Cholesterol, LDLLipoprotein(a)Treatment Outcome

Stichwörter der Autor:innen

acute coronary syndromeapolipoprotein(a)immunoassaylipoprotein(a)mass spectrometry

Substanzen

PCSK9 protein, humanProprotein Convertase 9Cholesterol, LDLLipoprotein(a)Anticholesteremic AgentsHydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • Division of Cardiology, University of Colorado School of Medicine, Aurora (M. Szarek, G.G.S.).
  • CPC Clinical Research, Aurora, CO (M. Szarek).
  • State University of New York, Downstate Health Sciences University, Brooklyn (M. Szarek).
  • Departments of Clinical Chemistry and Laboratory Medicine (E.R., L.R.R., C.C.), Leiden University Medical Center, the Netherlands.
  • Cardiology (J.W.J.), Leiden University Medical Center, the Netherlands.
  • Netherlands Heart Institute, Utrecht (J.W.J.).

ORCID-Profile: Michael Szarek, Esther Reijnders, J Wouter Jukema, Deepak L Bhatt, Vera A Bittner, Rafael Diaz, Sergio Fazio, Shaun G Goodman, Robert A Harrington, L Renee Ruhaak, Sotirios Tsimikas, Harvey D White, P Gabriel Steg, Christa Cobbaert, Gregory G Schwartz

Zitieren

APA

Szarek, M., Reijnders, E., Jukema, J. W., Bhatt, D. L., Bittner, V. A., Diaz, R., Fazio, S., Garon, G., Goodman, S. G., Harrington, R. A., Ruhaak, L. R., Schwertfeger, M., Tsimikas, S., White, H. D., Steg, P. G., Cobbaert, C., Schwartz, G. G., & ODYSSEY OUTCOMES Investigators (2024). Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of 3 Tests. Circulation, 149(3), 192-203. https://doi.org/10.1161/circulationaha.123.066398

Vancouver

Szarek M, Reijnders E, Jukema JW, Bhatt DL, Bittner VA, Diaz R, et al. Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of 3 Tests. Circulation. 2024;149(3):192-203. doi:10.1161/circulationaha.123.066398

BibTeX
@article{Szarek2024,
  author = {Szarek, Michael and Reijnders, Esther and Jukema, J Wouter and Bhatt, Deepak L and Bittner, Vera A and Diaz, Rafael and Fazio, Sergio and Garon, Genevieve and Goodman, Shaun G and Harrington, Robert A and Ruhaak, L Renee and Schwertfeger, Markus and Tsimikas, Sotirios and White, Harvey D and Steg, P Gabriel and Cobbaert, Christa and Schwartz, Gregory G and ODYSSEY OUTCOMES Investigators, ODYSSEY OUTCOMES Investigators},
  title = {Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of 3 Tests},
  journal = {Circulation},
  year = {2024},
  volume = {149},
  number = {3},
  pages = {192--203},
  doi = {10.1161/circulationaha.123.066398}
}
Kostenlos starten →